Why it matters
Regulators and payers increasingly consider real-world data alongside clinical trials. Access to high-quality data, and the governance to share it, is becoming a competitive capability.
Real-world data comes from health records, registries, claims and devices. Its value for decisions depends on data quality, consistent definitions and governance that patients and regulators trust.
By the numbers
What's changing
- The European Health Data Space creates a framework for the secondary use of health data.
- Regulators are publishing guidance on the use of real-world evidence in decisions.
- Federated analysis allows research without moving patient data.
How leaders are responding
- Building partnerships with data holders under clear governance.
- Investing in data standards and quality assessment.
- Using privacy-enhancing technologies for analysis.
What good looks like
- Data governance ready for requests through health data access bodies
- Real-world evidence studies designed with regulators early
- Privacy-preserving analysis, such as secure processing environments
What to watch
- Implementation of the European Health Data Space.
- Regulatory guidance on real-world evidence in submissions.
- Federated data networks across countries.
Where to start
Questions for your leadership team
- Which decisions would real-world evidence support?
- How good is the data we can access?
- How do we demonstrate trustworthy governance?

